Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Argenx Se ADR (NQ: ARGX )

476.62 +3.85 (+0.81%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 4, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 276,924
Open 482.63
Bid (Size) 469.14 (1)
Ask (Size) 483.81 (1)
Prev. Close 472.77
Today's Range 472.76 - 485.90
52wk Range 333.07 - 550.76
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
Via Benzinga
Stock Market Rally Attempt Underway; Micron, Nike, Amazon, Meta In Focus: Weekly Review
But it's not a confirmed uptrend yet. Nike, Amazon and Meta were in focus. 
Via Investor's Business Daily

Performance

YTD
+27.51%
+27.51%
1 Month
-7.27%
-7.27%
3 Month
+24.48%
+24.48%
6 Month
+27.72%
+27.72%
1 Year
+29.01%
+29.01%

More News

Read More
What's Going On Pfizer's Subsidiary Biohaven Stock?
Via Benzinga
Biohaven, Yet Another Argenx Rival In Autoimmune Drugs, Just Rocketed 29%
Via Investor's Business Daily
Why Immunovant Stock Is Bolting Higher Today
Via The Motley Fool
The Latest Analyst Ratings for argenx
Via Benzinga
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today
Via Benzinga
What 20 Analyst Ratings Have To Say About argenx
Via Benzinga
Immunovant Parlays Its Shot At Rivaling Argenx Into A $300 Million Offering
Via Investor's Business Daily
Immunovant Soars 73% — And Slugs Argenx — As Autoimmune Disease Battle Heats Up
Via Investor's Business Daily
Argenx's 28% Surge & Promising Product Propel Investor Confidence
Via MarketBeat
argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis
From argenx SE
Via GlobeNewswire
This New S&P 500 Entrant Leads 5 Stocks Near Buy Points
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Here's How Much $1000 Invested In argenx 5 Years Ago Would Be Worth Today
Via Benzinga
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
Via Benzinga
argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis
From argenx SE
Via GlobeNewswire
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
Top AI Stock ANET Leads 5 Stocks Near Buy Points In Tough Market
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Is Argenx Stock a Buy Now?
Via The Motley Fool
Earnings Outlook For argenx
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023
Via Benzinga
argenx Reports Half Year 2023 Financial Results and Provides Second Quarter Business Update
From argenx SE
Via GlobeNewswire
Argenx Stock Rides 'Megabuster' Drug Excitement To 40% Gain Before Earnings
Via Investor's Business Daily
argenx announces closing of global offering
From argenx SE
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.